On June 3, 2021, Helix, the leading population genomics and COVID-19 testing company, announced that it has closed a $50 million Series C funding round led by existing investors Warburg Pincus, DFJ Growth, Kleiner Perkins Caufield Byers, Mayo Clinic, and Temasek. Wilson Sonsini Goodrich & Rosati advised Temasek on the transaction.

The proceeds from the financing will be used to accelerate Helix’s population genomics platform across health systems, life sciences companies, and payers, as well as power its growing COVID-19 testing and viral surveillance efforts. Helix's end-to-end genomics platform enables organizations to advance genomic research and accelerate the integration of genomic data into clinical care through its unique “Sequence Once, Query Often™” model. With this model, an individual's DNA can be collected, sequenced, and securely stored once, while allowing continuous access to the genomic data and insights as needed, without collecting additional saliva samples.

The Wilson Sonsini team that advised Temasek on the financing included:

Corporate
Barry Taylor
Adam Bloom

CFIUS
Stephen Heifetz
Anne Seymour
Nimit Dhir

Tax
Jonathan Zhu


For more information, please see Helix’s press release.